News Ipsen

Stocks

IPN

FR0010259150

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-06-26 EDT			Pre-market 01:16:02
162.40 ^EUR	+0.12%		162.60	+0.12%

06-23	THX Pharma appoints Sophie Jacq Lapointe to its board of directors
06-12	Could This Finally Be the One?

All News

Mentions Relevance

01:00am	Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline	GL
06-22	IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2026	GL
06-15	IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2026	GL
06-09	Ipsen : welcomes the European Union’s publication of the Joint Clinical Assessment for Ojemda® (tovorafenib)	PU
06-08	IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2026	GL
06-05	HC Wainwright Starts Ipsen Coverage with Buy Rating	MT
06-02	For final dividend	FA
06-01	Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns	RE
06-01	IPSEN - Buy-back programme - Art 5 of MAR - Week 22 - 2026	GL
05-29	Ipsen launches its fifth global employee share ownership plan
05-29	Ipsen announces the launch of an Employee Shareholding Plan	GL
05-28	Ipsen Price Target, Estimates Up as AlphaValue/Baader Europe Notes Upcoming Data Readouts, Product Mix	MT
05-28	Ipsen Presents New Late-Breaking Results and Real-World Evidence for IQIRVO in Primary Biliary Cholangitis	CI
05-28	Ipsen announces new positive data for Iqirvo
05-28	Ipsen's IQIRVO shows meaningful fatigue improvements in moderate-to-severe PBC patients	RE
05-28	New late-breaking data reinforces IQIRVO®’s impact on ALP, fatigue and pruritus in PBC	GL
05-27	IPSEN - Buy-back programme - Art 5 of MAR - Week 21 - 2026	GL
05-27	Ipsen: Beneficiary of favourable product mix and imminent readouts
05-20	National Survey From Ipsen Shows Young People Are Not Prepared for the Shift From Pediatric to Adult Healthcare	BU
05-20	Ipsen announces late-breaking data from first head-to-head study comparing Dysport and Botox in adults with upper limb spasticity	AQ
05-20	Ipsen reports positive Phase IV data in ULS
05-19	Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity	GL
05-19	Ipsen Announces Late-Breaking Data from First Head-To-Head Study Comparing Dysport and Botox in Adults with Upper Limb Spasticity	CI
05-18	Ipsen S.A. - Special Call
05-18	Ipsen retreats despite encouraging clinical updates